Business
Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics and Biomarkers
-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions -- -- Expected
About this update from Inotiv, Inc.
[{"type":"text","content":"-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions -- -- Expected to enhance scale, broaden customer base and create significant cross-selling opportunities -- WEST LAFAYETTE, Ind., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and Synexa Life Sciences (“Synexa”), a world leader in clinical biomarker and bioanalysis research services, today jointly announced that they intend to form a collaboration that will accelerate Inotiv’s development of biomarkers essential to the understanding of safety and efficacy of novel biotherapeutics, enhancing the Company’s core preclinical discovery and safety assessment services. This collaboration will provide Synexa with further international expansion of its clinical biomarker and bioanalytical offering. Under this commercial collaboration, Synexa will support Inotiv in developing and delivering comprehensive GLP biomarker and biotherapeutics bioanalytical services, and Synexa will lease laboratory space at Inotiv’s Rockville, MD, site to establish U.S. operations. “The evolving complexity of novel biotherapeutics, such as cell and gene therapies, requires laboratories with real expertise to develop and validate methods and to perform analysis in the preclinical and clinical fields to satisfy the scrutiny of international regulatory authorities throughout the entirety of the drug development process,” said Kenneth Swart, Ph.D., Inotiv’s Senior Vice President of Bioanalytical and Biotherapeutic Sciences. “The complementary service offerings of Inotiv and Synexa will allow us to combine deep expertise and scientific capabilities to build a comprehensive bioanalytical and biomarker solution in the field of biotherapeutics with a priority to support our clients’ molecules from discovery into regulated preclinical (GLP) analysis.” “We are very excited to combine forces with Inotiv in such a promising new collaboration,” said Synexa CEO Paul O’Riordan. “Our clients need new solutions in an ever more complex drug development environment, and a seamless transition from the prec...